WO2001075449A1 - Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif - Google Patents

Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif Download PDF

Info

Publication number
WO2001075449A1
WO2001075449A1 PCT/JP2001/002723 JP0102723W WO0175449A1 WO 2001075449 A1 WO2001075449 A1 WO 2001075449A1 JP 0102723 W JP0102723 W JP 0102723W WO 0175449 A1 WO0175449 A1 WO 0175449A1
Authority
WO
WIPO (PCT)
Prior art keywords
assaying
mdm2
autoantibody against
cancer
reagent therefor
Prior art date
Application number
PCT/JP2001/002723
Other languages
English (en)
French (fr)
Inventor
Yuko Seino
Original Assignee
Nippon Kayaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kabushiki Kaisha filed Critical Nippon Kayaku Kabushiki Kaisha
Priority to EP01917677A priority Critical patent/EP1271152A4/en
Priority to CA002405448A priority patent/CA2405448A1/en
Priority to AU44650/01A priority patent/AU4465001A/en
Priority to US10/240,231 priority patent/US20040248216A1/en
Publication of WO2001075449A1 publication Critical patent/WO2001075449A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2001/002723 2000-03-30 2001-03-30 Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif WO2001075449A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01917677A EP1271152A4 (en) 2000-03-30 2001-03-30 METHOD FOR DETECTING CANCER BY MEASURING AUTOANTIC VIRUSES AGAINST MDM2 AND REAGENTS THEREFOR
CA002405448A CA2405448A1 (en) 2000-03-30 2001-03-30 Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
AU44650/01A AU4465001A (en) 2000-03-30 2001-03-30 Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US10/240,231 US20040248216A1 (en) 2000-03-30 2001-03-30 Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-93569 2000-03-30
JP2000093569 2000-03-30

Publications (1)

Publication Number Publication Date
WO2001075449A1 true WO2001075449A1 (fr) 2001-10-11

Family

ID=18608736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/002723 WO2001075449A1 (fr) 2000-03-30 2001-03-30 Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif

Country Status (5)

Country Link
US (1) US20040248216A1 (ja)
EP (1) EP1271152A4 (ja)
AU (1) AU4465001A (ja)
CA (1) CA2405448A1 (ja)
WO (1) WO2001075449A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1451587A2 (en) * 2001-11-09 2004-09-01 Benaroya Research Institute at Virginia Mason Antigen panels and methods of using the same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1872136B9 (en) 2005-04-04 2023-02-08 Biogen MA Inc. Methods and products for evaluating an immune response to a therapeutic protein
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
KR20080104343A (ko) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
US7776605B2 (en) 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
CA2667012A1 (en) * 2006-10-26 2008-05-02 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
CA2776756A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
LT3339865T (lt) 2010-01-11 2022-12-12 Biogen Ma Inc. Tyrimas, skirtas antikūnams prieš jc virusą nustatyti
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
JP6243838B2 (ja) 2011-05-31 2017-12-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｐｍｌの危険性を査定する方法
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014233A2 (de) * 1993-11-19 1995-05-26 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Nachweisverfahren für hdm-2-spezifische antikörper
DE4339533A1 (de) * 1993-11-19 1995-06-14 Deutsches Krebsforsch Nachweisverfahren für hdm-2 spezifische Antikörper

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014233A2 (de) * 1993-11-19 1995-05-26 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Nachweisverfahren für hdm-2-spezifische antikörper
DE4339533A1 (de) * 1993-11-19 1995-06-14 Deutsches Krebsforsch Nachweisverfahren für hdm-2 spezifische Antikörper

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER LETTERS, vol. 96, 1995, pages 111 - 115, XP002941458 *
NATURE, vol. 358, 1992, pages 80 - 83, XP002941459 *
See also references of EP1271152A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1451587A2 (en) * 2001-11-09 2004-09-01 Benaroya Research Institute at Virginia Mason Antigen panels and methods of using the same
EP1451587A4 (en) * 2001-11-09 2006-12-06 Benaroya Res Inst At Virginia ANTIGENTAFELN AND METHOD FOR THEIR USE

Also Published As

Publication number Publication date
CA2405448A1 (en) 2001-10-11
EP1271152A4 (en) 2005-04-27
US20040248216A1 (en) 2004-12-09
EP1271152A1 (en) 2003-01-02
AU4465001A (en) 2001-10-15

Similar Documents

Publication Publication Date Title
EP0914344B8 (en) ASSAY AND REAGENTS FOR QUANTIFYING hBNP
WO1999041584A3 (en) METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY hCG ASSAY
GB2374415B (en) Human antibodies as detection reagents
AU1137301A (en) Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool
AU9648301A (en) Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor
HK1089232A1 (en) Use of a midregional proadrenomedullin partial peptide in biological fluids in the production of immological diagnostic agents
WO2001075449A1 (fr) Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
AU2002351281A1 (en) Homogeneous immunoassays for multiple allergens
IL146454A0 (en) METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY hCG ASSAY
WO2002090961A3 (en) Systems and methods for detection of analytes in biological fluids
NZ330475A (en) Antibodies, and use thereof in measuring lipid peroxidation in biological samples and method for inducing inflammation
WO2005106494A3 (en) Monoclonal antibodies, hybridomas, improved method for determining the protein ptx3 and kit for said determination
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
AU3059499A (en) Solid-phase method for antigen and antibody determinations in bloodgroup serology, and test kit
WO2003016907A1 (fr) Reactif de dosage pour antigene de la laminine 5 dans un echantillon biologique et procede de dosage
EP1072888A3 (en) Immunoassay method and reagent for HIV-1p24 antigen
AU2002233800A1 (en) Method and kit for predicting cancer
EP1347298A3 (en) Immunoassay method, test strip for use therein, and immunoassay apparatus
AU6688700A (en) Diagnostic assay for human matrix gla-protein and its use as a biomarker
WO2005114203A3 (en) Dominant b cell epitopes and methods of making and using thereof
CA2349217A1 (en) Cancer-associated antigens and methods of their identification
AU2640399A (en) Method for immunochemically assaying anti-hm1.24 antibody
WO2002090989A3 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
EP1245957A3 (en) Method of measuring ceruloplasmin concentration with enzyme-linked immunosorbent assay or dissociation-enhanced time-resolved fluoroimmunoassay in a blood spot, and Wilson's disease screening kit and method of diagnosing Wilson's disease
EP0271810A3 (en) Immunological determination of free human protein s and c4bp-protein s complex

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10240231

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2405448

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001917677

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 44650/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001917677

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001917677

Country of ref document: EP